The Patient Activation Measure: a validation study in a neurological population

被引:34
|
作者
Packer, Tanya L. [1 ]
Kephart, George [2 ]
Ghahari, Setareh [3 ,4 ]
Audulv, Asa [1 ,5 ]
Versnel, Joan [1 ]
Warner, Grace [1 ]
机构
[1] Dalhousie Univ, Sch Occupat Therapy, Halifax, NS B3H 4R2, Canada
[2] Dalhousie Univ, Community Hlth & Epidemiol, Halifax, NS B3H 4R2, Canada
[3] Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada
[4] Univ Social Welf & Rehabil Sci, Dept Occupat Therapy, Tehran, Iran
[5] Mid Sweden Univ, Dept Nursing, Sundsvall, Sweden
关键词
Chronic disease management; Measurement; Validation; Neurological conditions; Patient activation; PAM-13; SHORT-FORM; SELF-MANAGEMENT; MEASURE PAM; EMPLOYEES HEALTH; PEOPLE; INDIVIDUALS; TRANSLATION; SCLEROSIS; OUTCOMES; QUALITY;
D O I
10.1007/s11136-014-0908-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
To assess the validity of the Patient Activation Measure (PAM13) of patient activation in persons with neurological conditions. "The Everyday Experience of Living with and Managing a Neurological Condition" (The LINC study) surveyed 948 adults with neurological conditions residing in Canada in 2011 and 2012. Using data for 722 respondents who met coding requirements for the PAM-13, we examined the properties of the measure using principle components analysis, inter-item correlations and Cronbach's alpha to assess unidimensionality and internal consistency. Rasch modeling was used to assess item performance and scaling. Construct validity was assessed by calculating associations between the PAM and known correlates. PAM-13 provides a suitably reliable and valid instrument for research in patients with neurological conditions, but scaling problems may yield measurement error and biases for those with low levels of activation. This is of particular importance when used in clinical settings or for individual client care. Our study also suggests that measurement of activation may benefit from tailoring items and scaling to specific diagnostic groups such as people with neurological conditions, thus allowing the PAM-13 to recognize unique attributes and management challenges in those conditions. The PAM-13 is an internally reliable and valid tool for research purposes. The use of categorical activation "level" in clinical settings should be done with caution.
引用
收藏
页码:1587 / 1596
页数:10
相关论文
共 50 条
  • [21] Adaptation and validation of the German Patient Activation Measure for adolescents with chronic conditions in transitional care: PAM® 13 for Adolescents
    Bomba, Franziska
    Markwart, Henriette
    Muehlan, Holger
    Menrath, Ingo
    Ernst, Gundula
    Thyen, Ute
    Schmidt, Silke
    RESEARCH IN NURSING & HEALTH, 2018, 41 (01) : 78 - 87
  • [22] Psychometric Properties of the Patient Activation Measure in Family Caregivers of Patients With Chronic Illnesses
    Lin, Chin-Yen
    Chung, Misook L.
    Schuman, Donna L.
    Biddle, Martha J.
    Mudd-Martin, Gia
    Miller, Jennifer L.
    Hammash, Muna
    Schooler, Mary P.
    Rayens, Mary Kay
    Feltner, Frances J.
    Moser, Debra K.
    NURSING RESEARCH, 2023, 72 (04) : 292 - 300
  • [23] Translation and Validation of the Patient Activation Measure in Portuguese People with Type 2 Diabetes Mellitus
    Laranjo, Liliana
    Dias, Vera
    Nunes, Carla
    Paiva, Dagmara
    Mahoney, Bill
    ACTA MEDICA PORTUGUESA, 2018, 31 (7-8) : 382 - 390
  • [24] Relationships between patient activation, disease-specific knowledge and health outcomes among people with diabetes; a survey study
    Hendriks, Michelle
    Rademakers, Jany
    BMC HEALTH SERVICES RESEARCH, 2014, 14
  • [25] Knowing in Nurses' Belief and Attitude about Patient Activation: A Validation of the Korean Clinician Support for Patient Activation Measure Using Rasch Analysis
    Choi, Suhyeon
    Ham, Yun Hee
    Han, Kihye
    Ryu, Eunjung
    HEALTHCARE, 2020, 8 (04)
  • [26] Measuring patient activation in Italy: Translation, adaptation and validation of the Italian version of the patient activation measure 13 (PAM13-I)
    Graffigna, Guendalina
    Barello, Serena
    Bonanomi, Andrea
    Lozza, Edoardo
    Hibbard, Judith
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2015, 15
  • [27] Does patient activation predict the course of type 2 diabetes? A longitudinal study
    Sacks, Rebecca M.
    Greene, Jessica
    Hibbard, Judith
    Overton, Valerie
    Parrotta, Carmen D.
    PATIENT EDUCATION AND COUNSELING, 2017, 100 (07) : 1268 - 1275
  • [28] Validation of the Patient Activation Measure (PAM-13) among adults with cardiac conditions in Singapore
    Bi Xia Ngooi
    Tanya L. Packer
    George Kephart
    Grace Warner
    Karen Wei Ling Koh
    Raymond Ching Chiew Wong
    Serene Peiying Lim
    Quality of Life Research, 2017, 26 : 1071 - 1080
  • [29] Fidelity or flexibility: An ethnographic study of the implementation and use of the Patient Activation Measure
    Chew, Sarah
    Brewster, Liz
    Tarrant, Carolyn
    Martin, Graham
    Armstrong, Natalie
    PATIENT EDUCATION AND COUNSELING, 2018, 101 (05) : 932 - 937
  • [30] Adaptation to European Spanish and psychometric properties of the Patient Activation Measure 13 in patients with chronic diseases
    Moreno-Chico, Cibeles
    Gonzalez-de Paz, Luis
    Monforte-Royo, Cristina
    Arrighi, Emilia
    Dolores Navarro-Rubio, M.
    Gallart Fernandez-Puebla, Alberto
    FAMILY PRACTICE, 2017, 34 (05) : 627 - 634